Arrowhead grabs RNAi delivery assets in Roche deal

Arrowhead Research ($ARWR) has parachuted into the bombarded field of RNAi therapeutics armed with Swiss drug giant Roche's assets. As part of Pasadena, CA-based Arrowhead's acquisition of Roche's stake in the gene-silencing drugs, the firm picked up three drug-delivery technologies. The technologies include a delivery platform called "Dynamic PolyCunjugates" (DPCs), a license to "SNALP" delivery tech from Tekmira Pharamceuticals ($TKM), and Roche-developed liposomal nanoparticle RNAi carriers. Roche is among several Big Pharma groups that have made major cuts to internal research of RNAi drugs. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.